,92 Whether CCS patients with prognostically relevant major periprocedural myocardial injury, who are not already on ACE-inhibitors (for heart failure, hypertension, or diabetes) or beta-blockers (for left ventricular dysfunction or systolic heart failure), would benefit from the addition of these pharmacotherapies to reduce the risk of future MACE is not known, and needs to be evaluated in further studies. This evidence concerns the gene ACE and hypertensive disorder.